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Preconception allergen sensitization can 
induce B10 cells in offspring: a potential main 
role for maternal IgG
Marília Garcia de Oliveira1, Luana de Mendonça Oliveira1, Aline Aparecida de Lima Lira1, Fábio da 
Ressureição Sgnotto1, Alberto José da Silva Duarte1,2, Maria Notomi Sato1 and Jefferson Russo Victor1,2* 
Abstract 
Background: The mechanisms through which allergies can be inhibited after preconception immunization with 
allergens are not fully understood. We aimed to evaluate whether maternal immunization can induce a regulatory B 
(B10) cell population in offspring in concert with allergy inhibition.
Methods: C57BL/6 females were or were not immunized with OVA and were mated with normal WT males. Their off-
spring were evaluated at 3 days of age or 20 days after neonatal immunization. Human peripheral B cells from atopic 
and non-atopic individuals were also evaluated.
Results: Preconception OVA immunization induced B10 cells in offspring, and IL-10 production appeared to be criti-
cal for FcγRIIB upregulation in offspring B cells. Murine and human IL-10-producing B cells responded in vitro to IgG 
according to the atopic repertoire of the cells.
Conclusions: Our results reveal that maternal immunization induces allergen-specific B10 cells in offspring and a 
pivotal role for the IgG repertoire in IL-10 production by murine and human B cells.
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Background
Our group has studied type I hypersensitivity inhibi-
tion in murine models for the last decade [1–7]. Dur-
ing this period, we proposed that maternal IgG can play 
a pivotal role in offspring immune modulation, but the 
mechanisms underlying this phenomenon were not fully 
elucidated. In the 90s, it was revealed that maternal anti-
bodies are passively transferred to offspring during the 
gestational and weaning periods. These antibodies, par-
ticularly IgG, can interact directly with the offspring’s 
immune system, even in the absence of antigens [8], and 
might involve maternal antibody-allergen immune com-
plexes that directly interact with the inhibitory receptor 
FcγRIIb (CD32b) expressed by offspring B cells [9]. These 
interactions can in turn regulate the production of IgE 
antibodies, thus inhibiting the development of allergies. 
The alterations in the offspring immune system that 
occur as a consequence of maternal IgG interactions are 
not fully understood. Because the main event of allergy 
inhibition is the control of IgE production by B cells, we 
believe that this population plays a pivotal role as the 
subject of the effects induced by maternal immunization.
Some populations of B cells can acquire regula-
tory properties (Breg), and among these cell popu-
lations, regulatory B (B10) cells, which have been 
identified in humans and mice, have high regulatory 
potential [10]. This population is characterized by a 
 CD19+IL10+CD1dhigh phenotype and high IL-10 secre-
tion. The regulatory potential of B10 cells can inhibit 
OVA-induced allergic pulmonary inflammation [11]. The 
mechanism through which allergen-specific B10 cells can 
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be induced and a possible role of IgG in this mechanism 
have not been described.
The aim of this study was to determine whether mater-
nal immunization can induce regulatory B10 cells in off-
spring as a mechanism of allergy inhibition. Furthermore, 
we evaluated the importance of maternal IgG for the 
induction of B10 cells and whether evidence of similar 
mechanisms can be detected in humans.
Methods
Mice
C57BL/6 inbred wild-type (WT) or IL-10-genetically-
deficient male and female mice were used at 8–10 weeks 
of age. The animals were purchased through the Central 
Animal Facility of the School of Medicine and Institute 
of Biomedical Sciences—USP. The offspring (F1) of both 
sexes were evaluated during the neonatal period, and 
samples from at least three independent experiments 
were studied.
Patient samples
Peripheral blood mononuclear cells (PBMCs) and sera 
were collected from volunteers who were previously clas-
sified as atopic or non-atopic individuals according to 
their clinical status and who voluntarily submitted to a 
skin prick test (SPT) to confirm their atopic state. These 
individuals were classified into two groups: atopic indi-
viduals [clinically allergic and reactive to at least two 
allergens, n =  14, age (mean ±  SE) =  31.1 ±  2.86] and 
non-atopic individuals [without any clinical allergy symp-
toms and unreactive to any tested allergen, n =  14, age 
(mean ± SE) = 28.2 ± 3.11].
Each PBMC sample was provided by a different donor 
and analyzed in three independent experiments.
SPT and collection of blood samples
The subjects voluntarily submitted to a SPT according to 
European standards [12] with an adapted panel of aller-
gens that included the Brazil pattern (Blomia tropica-
lis, Canis familiaris, Periplaneta americana, Aspergillus 
fumigatus, Penicillium notatum, Alternaria alternata, 
Cladosporium herbarum, Dermatophagoides pteronyssi-
nus, Dermatophagoides farinae, and Felis domesticus).
In brief, a drop of each allergen extract, histamine 
(positive control) or allergen diluent (negative control—
IPI-Asac, Brazil) was applied to the volar aspect of the 
forearm. A superficial skin puncture was made through 
each allergen or control drop with a hypodermic lancet 
(Alko, Brazil) without inducing bleeding. Fifteen minutes 
after puncture, the transverse diameter of each wheal 
reaction was measured. We considered a reaction to be 
positive when the wheal was 3 mm greater than the wheal 
diameter of the negative control. As exclusion criteria, we 
adopted the use of antihistamines, glucocorticosteroids 
and some other systemic drugs that can influence the 
results 15 days before the test. We also excluded volun-
teers with severe eczema or dermographism.
Purification of mouse and human IgG
IgG antibodies were purified from the sera of mice that 
were immunized with OVA (40 days after immunization) 
or of non-immunized mice using a Melon Gel IgG Spin 
Purification kit, according to the manufacturer’s instruc-
tions (Thermo, USA). In brief, 500 μL of purification gel 
was placed in a mini column attached to a microtube, 
and the mixture was centrifuged for 1 min at 2000g. After 
the supernatant was discarded, 300 μL of washing buffer 
from the kit was added, and the resulting mixture was 
centrifuged again. The sample of pooled sera was added 
to the gel, homogenized for 5 min, and centrifuged, and 
the supernatant (purified IgG) was collected and stored 
at −70 °C for subsequent use in culture experiments.
To purify human IgG, two blood samples were obtained 
by venipuncture from each atopic or non-atopic individ-
ual in tubes without anticoagulants. After the blood sam-
ples were centrifuged at 1400g for 10 min, the serum was 
fractionated and pooled. Human IgG was purified using 
the Melon Gel IgG Spin Purification kit as described 
above, and the purified IgG was stored at −70 °C for sub-
sequent use in culture experiments.
Both purified IgGs were sterilized using 0.20-micron 
filters (Corning, Germany), and their IgG concentra-
tions were determined with the Coomassie Protein Assay 
Reagent (Pierce, USA) according to the manufacturer’s 
instructions.
Murine immunization
Female WT mice were immunized subcutaneously 
with 6  mg of Alum (FURP, Sao Paulo) only or supple-
mented with 1500  μg of OVA (EndoFit™—endotoxin 
levels  <1  EU/mg; InvivoGen, San Diego, CA, USA), 
100  μg of myelin oligodendrocyte glycoprotein (MOG) 
peptide fragment 35–55 (Sigma, USA) or 100  μg of Dp 
(LoTox—Indoor Biotechnologies, USA). These ani-
mals where boosted intraperitoneally (i.p.) after 10 and 
20 days with the same immunization antigen at the fol-
lowing doses: 1000 μg of OVA, 100 μg of MOG or 100 μg 
of Dp in saline. Thee females that were immunized with 
Alum only were boosted with saline alone. All females 
were mated 21  days post-immunization. The pups were 
maintained with their respective mothers during the 
breast-feeding period. Some groups of offspring from the 
immunized and non-immunized mothers were immu-
nized with the same antigen used for maternal immuni-
zation. Specifically, 3-day-old offspring were treated i.p. 
with 100 μg of OVA or 10 μg of Dp in 0.6 mg of Alum 
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and boosted after 10 days with the same antigen/dose in 
saline. Experimental analyses of the offspring were per-
formed at 20  days of age. The OVA immunization pro-
tocols were also performed using IL-10−/− or IL-10−/+ 
mice.
Determination of the total IgE and anti‑OVA IgG1/IgM 
antibody levels
The OVA-specific IgG1, IgM and total IgE antibodies 
were measured by ELISA as previously described [13]. 
To measure the total IgE level, a standard curve was used 
(Pharmingen, USA). The anti-OVA and anti-Dp Ab levels 
are expressed as optical densities. The anaphylactic anti-
OVA IgE titer was measured through passive cutaneous 
anaphylaxis (PCA) as previously described [7].
Murine lung inflammation
The offspring from either immunized or non-immunized 
mothers were immunized and nasally administered 
100 μg of OVA (InvivoGen, San Diego, CA, USA) at 43, 
50, 57, 58 and 59 days of age. The bronchoalveolar fluid 
(BAL) was analyzed at 60  days of age following exsan-
guination of the abdominal aorta. The BAL was obtained 
by washing the lungs three times with 1.5  mL of PBS 
using a tracheal tube followed by centrifugation at 2000g 
for 10 min. The cell pellet was diluted in 300 μL of PBS, 
and the total leukocyte counts were performed using a 
Neubauer chamber. Sections were cut at a thickness of 
3 µm, mounted on slides and stained with HE for mor-
phological analyses. The lungs were surgically collected 
and subjected to a tissue dissociation protocol.
Spleen cell suspensions
The spleens were collected, and their cells were isolated 
for culture or flow cytometry analyses. Single-cell sus-
pensions were prepared with cell strainers (BD Bio-
sciences, MA, USA) and placed in Petri dishes containing 
RPMI 1640 culture medium (Sigma, USA). The cell sus-
pension was treated with lysis buffer (Biosource—ACK 
Lysis Buffer, Rockville, MD, USA) for 2 min, and the cell 
suspension was washed twice with RPMI medium. The 
cells were subsequently resuspended in 1  mL of RPMI 
medium with 10% FBS (III HyClone, Logan, UT, USA), 
and the cellular viability was quantified with 0.5% Trypan 
blue in a Neubauer chamber.
Murine flow cytometry
For surface staining, single-cell suspensions were pre-
pared in flow cytometry buffer (PBS, 1% BSA). Anti-
CD19 (1D3), anti-B220 (RA3-6B2), anti-CD1d (1B1), 
anti-IgM (R6-60.2) or anti-CD16/32 (2.4G2) antibodies 
directly conjugated to Cy-Chrome, PE, APC, Horizon 
V450, PE-Texas Red, PerCP, PerCP-Cy5 or FITC (BD 
Biosciences) were used at their optimal concentrations, 
as determined through titration experiments. Cell gating 
was based on the specific isotype control values as well as 
the fluorochrome minus 1 (FMO) setting when needed. 
The gating strategy for B cells that produce IL-10 and B10 
cells is illustrated in Additional file 1: Figure S1. All anal-
yses were performed using FlowJo software (Tree Star 
Inc.). For intracellular staining, the cells were first sur-
face-stained, fixed (PBS, 1% formaldehyde—Sigma), per-
meabilized (PBS, 0.5% Saponin—Sigma), and subjected to 
intracellular staining with IL-10 (JES5-16E3) or a match-
ing isotype. For the evaluation of intracellular cytokines, 
the cells were cultured for 24  h at 3  ×  106 cells/mL in 
RPMI 1640 (Gibco) supplemented with 10% heat-inac-
tivated FCS (HyClone) without stimulus in the presence 
of 10  mg/mL brefeldin A during the last 12  h (Sigma-
Aldrich). After the staining of surface markers, the cells 
were fixed with 4% formaldehyde in PBS (Merck) and 
then subjected to intracellular staining. Instrument com-
pensation was performed using micro beads adsorbed 
with anti-rat/anti-hamster antibodies (CompBeads, BD 
Biosciences) and their conjugated antibodies. The acqui-
sition of 50,000 events per sample was performed in the 
lymphocyte quadrant (as determined by the ratio of size 
to granularity) on an LSRFortessa cytometer (BD Bio-
sciences, USA), and data analysis was performed using 
FlowJo software 7.6.5 (Tree Star, USA).
For the measurement of serum cytokines, the Th1/
Th2/Th17A mouse CBA kit (Cytometric Bead Assay, 
BD Biosciences) was used according to the manufac-
turer’s instructions. In brief, microspheres of different 
fluorochrome intensities were sensitized with anti-IL-6 
and anti-IL-10 and incubated either with the serum or 
supernatant for the generation of a standard curve or in 
the presence of capture antibodies for the same cytokine 
conjugated to PE for 2  h at room temperature. After 
washing with buffer supplied by the manufacturer, the 
microspheres were analyzed with an LSRFortessa cytom-
eter (BD Biosciences, USA), and the levels were deter-
mined using CBA Analysis Software.
The BAL was prepared in PBS, and red blood cells 
were lysed using ammonium chloride lysis buffer. The 
BAL cells were stained as described by van Rijt et  al. 
[14] with the optimal concentrations of the following 
monoclonal antibodies provided by BD Biosciences (San 
Diego, CA, USA): MHCII (2G9), CCR3 (101.111), CD11c 
(HL3), CD3 (145-2C11) and B220 (RA3-6B2). To prevent 
nonspecific binding to Fc receptors, a 2.4 G2-blocking 
reagent (6  µg/mL) was added to the monoclonal anti-
body mix. Lymphocytes were identified as FSClo/SSClo 
cells expressing CD3 or B220, and B cells were distin-
guished from T cells through MHCII expression in the 
(B220/CD3)+ gate. Granulocytes were recognized as 
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non-autofluorescent highly granular (SSChi) cells. Within 
this gate, eosinophils were defined as cells that expressed 
the eotaxin receptor CCR3, intermediate levels of CD11c, 
and very low to undetectable levels of MHCII, B220 and 
CD3. Neutrophils presented a similar scatter profile to 
eosinophils but lacked CCR3 expression. Dendritic cells 
were identified as (CD3/B220)+ cells and expressed high 
levels of MHCII and CD11c. Alveolar macrophages were 
identified as large autofluorescent cells.
Lung tissue dissociation
The lungs were collected through enzymatic dissocia-
tion and placed in 15-mL propylene conical centrifuge 
tubes. An enzymatic solution (2 mL) consisting of RPMI 
medium pre-warmed to 37  °C, 1  mg/mL collagenase D, 
2 mg/mL DNase I (Roche Diagnostics, Mannheim, Ger-
many), and 5% fetal bovine serum (FBS) was then added, 
and the sample was incubated for 15 min at 37 °C under 
continuous agitation. The digested tissue was homog-
enized gently and filtered through a plastic sieve with a 
70-μM mesh screen (Cell Strainer, BD Falcon, CA, USA) 
to remove aggregates. The resultant cell suspensions were 
washed twice with 10 mL of RPMI medium (Gibco—Life 
Technologies, NY, USA) pre-warmed to 37  °C and then 
centrifuged at 500g for 5 min.
Murine cell culture
To investigate the FcγRIIb expression kinetics in B cells, 
the phenotypes of 3 × 106 cells/mL normal adult splenic 
B cells were evaluated by flow cytometry ex vivo or after 
culture for 24, 48, 72 or 96 h in RPMI 1640 (Gibco) sup-
plemented with 10% heat-inactivated FCS (HyClone) in 
the presence of 50  μg/mL anti-IgM F(ab’)2 (Southern 
Biotech, USA).
To investigate the in  vitro effect of purified maternal 
antibodies on offspring B cells, splenocytes from 3-day-
old offspring of immunized or non-immunized moth-
ers were cultured for 120 h at a density of 3 × 106 cells/
mL in RPMI 1640 (Gibco) supplemented with 10% heat-
inactivated FCS (HyClone) in the presence of 20 μg/mL 
OVA (Grade V—Sigma, St. Louis, MO, USA) or 100 μg/
mL purified IgG from immunized or non-immunized 
mothers. Some culture wells were previously blocked 
with 10  μg/mL purified anti-CD16/32 (2.4G2). For the 
evaluation of intracellular cytokine production, all of the 
culture wells were given 10 mg/mL brefeldin A (Sigma-
Aldrich) 24 h before flow cytometric evaluation.
Separation of PBMCs
To obtain PBMCs from atopic or non-atopic individuals, 
blood samples of approximately 20  mL were collected 
by venipuncture in sodium heparin-containing tubes. 
The blood was diluted in physiological saline at a 1:1 
proportion of blood to saline. The blood was then placed 
in conical tubes containing Ficoll-Paque Plus (GE Health-
care, Sweden) at a proportion of 1:3. This material was 
centrifuged at 800g for 20 min, and the cells were subse-
quently washed twice in saline and resuspended in 1 mL 
of RPMI 1640 containing 10% fetal bovine serum (FBS). 
A sample of this suspension was diluted at a ratio of 1:2 
in Trypan blue for assessments of cell viability and counts 
under an optical microscope using a Neubauer chamber.
Human cell culture and flow cytometry
Thawed, freshly separated PBMCs were washed twice 
with 10  mL of RPMI medium at 37  °C, centrifuged at 
800g for 10 min, and resuspended in 1 mL of RPMI 1640 
medium containing 10% fetal bovine serum. A sample of 
this suspension was diluted 1:2 in Trypan blue (Sigma, 
USA) for evaluation of the cell viability and count under 
an optical microscope using a Neubauer chamber (Labo-
roptik, Germany). After dilution, 1 × 106 viable PBMCs 
were placed in each well of a culture plate and cultured 
with 100  μg/mL IgG, which was purified from pools of 
atopic or non-atopic individuals in RPMI 1640 medium 
containing 10% fetal bovine serum in a total volume of 
200 μL. The culture plate was incubated at 37 °C with 5% 
 CO2 for 6 days, which was the period determined based 
on the kinetic assessment. After incubation, 1  mg/mL 
brefeldin A was added (Sigma, Israel) to each well of the 
culture plate, and flow cytometry labeling was performed 
after 24 h.
For extracellular staining, PBMCs at a concentration of 
0.5 × 106 were transferred to test tubes, and 1 μL of each 
antibody was added to the cells (except the unlabeled 
tubes) and incubated for 30 min at 4 °C while protected 
from light. After 500 μL of 1X PBS solution was added, 
the tubes were centrifuged at 800g for 5 min. The super-
natant was discarded by inversion, and 300 μL of 1X PBS 
was added. For fixation, 200 μL of 1% formaldehyde was 
added for at least 10 min. The PBMCs were stained with 
mouse anti-human-CD4 conjugated to FITC or APC, 
anti-human-CD8 conjugated to PE and anti-human-
CD19 PE-Cy7 antibodies (BD Pharmingen, NJ, USA) for 
the identification of B cells  (CD4−CD8−CD19+).
For intracellular labeling, the tubes were centrifuged 
at 800g for 5  min, the supernatant was discarded, and 
1 μL of each antibody was added to the cells (except the 
unlabeled tubes). A 100-µL volume of 1X PBS containing 
0.05% saponin was added, and the tubes were stored at 
4 °C for 30 min while protected from light. After centrif-
ugation at 800g for 5 min, the supernatant was discarded 
by inversion, and the cells were resuspended in 300 μL of 
1X PBS solution. The PBMCs were stained with mouse 
anti-human IL-10 conjugated to Horizon V450 (BD 
Pharmingen, NJ, USA).
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The acquisition of 50,000 events per sample was per-
formed in the lymphocyte quadrant (as determined by 
the ratio of size to granularity) using an LSRFortessa 
cytometer (BD Biosciences, USA). Compensation was 
performed using the adsorbed microspheres with anti-
mouse antibodies (CompBeads, BD Biosciences, USA), 
and the same antibodies were used for extra and intra-
cellular staining. The cell gating protocol was based on 
the specific isotype control values as well as the fluo-
rochrome minus 1 (FMO) setting when needed. Data 
analysis was performed using FlowJo software (Tree Star, 
Ashland, OR, USA).
Statistical analysis
The statistical analyses were performed with Graph-
Pad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, 
USA). The data from the in vivo and in vitro studies were 
obtained from three to five separate experiments with 
nine to 15 mice per group or 14 atopic or non-atopic 
individuals. Differences were considered significant when 
P ≤ 0.05, as assessed by Student’s t test and the Mann–
Whitney test.
Results
At 20 days of age, the offspring from immunized mothers 
presented suppression of the total IgE and allergen-specific 
anaphylactic IgE titers compared with the offspring from 
non-immunized mothers. Moreover, increased specific 
IgG1 levels were detected in the offspring from immunized 
mothers compared with the offspring from non-immu-
nized mothers. An evaluation of specific IgM production 
revealed similar levels in the offspring from immunized 
or non-immunized mothers after neonatal immunization 
(Fig.  1a). Lung inflammation in 60-day-old immunized 
mice was evaluated through bronchoalveolar lavage fluid 
(BAL) and histological analyses, and maternal immuni-
zation induced significant protection against allergen-
induced airway inflammation, as evidenced by reductions 
in the numbers of neutrophils and eosinophils compared 
with the control group (Fig.  1b) and by the histological 
observation of a reduced cell-infiltrating profile (Fig. 1c).
We also found that the lung tissue infiltrating lym-
phocytes in the offspring from immunized mothers 
contained a higher amount of B cells that frequently 
produced IL-10 and expressed the B10 phenotype 
 (CD19+IL-10+CD1dhigh; Fig.  1d) than those identified 
in the offspring from non-immunized mothers. A sub-
sequent evaluation of the regulatory lymphocyte num-
bers on offspring spleens demonstrated that maternal 
OVA immunization substantially induced B10 cells in 
3-day-old offspring, and this induction was maintained 
at 20  days of age after neonatal immunization (Fig.  1e). 
We also evaluated whether maternal immunization with 
the adjuvant Alum alone or in combination with a puri-
fied non-allergenic protein (MOG) could induce B10 cells 
in offspring and observed no effect (Fig. 1e). Analyses of 
the offspring sera revealed that maternal immunization 
reduced systemic IL-6 production in immunized off-
spring (at 20  days of age) without influencing systemic 
IL-10 production compared with the levels observed in 
offspring from non-immunized mothers (Fig.  1f ). We 
also evaluated the impact of maternal immunization on 
FcγRIIb expression in offspring splenic B cells. Maternal 
immunization increased offspring FcγRIIb expression in 
 IgM+ B cells at three and 20  days of age after neonatal 
immunization (Fig. 1g).
Because maternal immunization induces an increase in 
offspring B10 cell frequency associated with RIIb upregu-
lation, we sought to confirm the role of IL-10 in FcγRIIb 
expression in normal B cells. Upon anti-IgM activation, 
IL-10−/− B cells showed the inability to overexpress FcγRIIB 
in response to anti-IgM activation compared with WT B 
cells (Fig. 2a). Based on this observation, we sought to ver-
ify the involvement of IL-10 by subjecting IL-10−/− mice 
to a maternal/neonatal immunization protocol and evalu-
ating the offspring with similar parameters to WT mice. 
The maternal immunization of IL-10−/− mice resulted in 
augmented levels of total IgE and specific IgG1 and IgM 
and decreased FcγRIIB expression in offspring B cells 
compared with that observed in WT mice (Fig.  2b). The 
effect of immunization on FcγRIIB expression in offspring 
B cells was maintained even in partially-IL-10-deficient 
hybrid mice (IL-10−/+; Fig. 2c). Our laboratory previously 
reported that the maternal Dermatophagoides pteronyssi-
nus (Dp) immunization protocol induces an opposite effect 
on FcγRIIB expression in offspring B cells compared with 
OVA [13], and we thus evaluated the induction of B10 cells 
in this model. Even at a higher dose of allergen than that 
used in our previous experiments, maternal Dp immuniza-
tion did not induce B10 cells in offspring, and the opposite 
effect on FcγRIIB expression was maintained (Fig. 2d).
We then evaluated the effects of in vitro OVA stimula-
tion on pup splenocytes in terms of the B10 percentage. 
As observed ex  vivo, the augmented B10 cell percentage 
was maintained in the splenocytes of pups from immu-
nized mothers after culture in the presence of OVA or 
IgG purified from immunized mothers compared with 
those from non-immunized mothers. We also investi-
gated whether the engagement of the FcγRIIB receptor is 
involved in the increased frequency of B10 cells observed 
in response to IgG using a FcγR-blocking antibody in vitro. 
We found that the culture of splenocytes of offspring from 
non-immunized mothers in the presence of immunized 
IgG resulted in a higher B10 cell frequency after FcγRIIB 
blocking compared with the frequency observed after cul-
ture without FcγRIIB blocking. Splenocytes of offspring 
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from immunized mothers yielded an even higher B10 cell 
frequency after FcγRIIB blocking (Fig. 2e).
To evaluate the hypothesis that B10 cells can respond 
to purified IgG in humans, PBMCs from atopic and non-
atopic individuals were evaluated in  vitro. Using the 
same period and IgG concentration that were used in 
the murine model, we found that B cells from non-atopic 
individuals cultured with autologous purified non-atopic 
IgG presented upregulated intracellular IL-10 produc-
tion compared with that detected with mock culture. 
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Fig. 1 Effects of preconception immunization on offspring antibody production, lung inflammation and phenotype. Offspring from immunized 
or non-immunized mothers were immunized with OVA in the neonatal period and evaluated at 20 days of age [20 (Im)]. The total IgE, anti-OVA 
IgG1 and anti-OVA IgM levels were determined by ELISA, and anaphylactic IgE was determined by PCA (a). BAL preparation, histological analysis 
and dissociation of offspring lungs were performed in 43-day-old offspring after five intranasal challenges. The differential cell counts in BAL were 
evaluated by flow cytometry (b). Histological examinations were performed on samples stained with H&E (c). The dissociated lungs were evaluated 
by flow cytometry (d). The number of spleen B10 cells (e), the serum cytokine levels (f) and splenic B cell FcγRIIb expression in offspring (g) from 
Alum-, OVA- or MOG-immunized (B10 cells only) or non-immunized mothers were also evaluated by flow cytometry at 3 days of age and after OVA 
immunization in the neonatal period at 20 days of age [20 (Im)]. A representative histogram of FcγRIIb expression in each group is shown. The data 
are presented as the mean ± SEM. *P≤0.05 compared with the respective offspring from non-immunized mothers
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This effect was not detected in response to heterologous 
atopic IgG. B cells from atopic patients did not produce 
IL-10 in response to autologous atopic IgG or heterolo-
gous non-atopic IgG compared with the mock culture 
(Fig. 3).
Discussion
The maternal immunization protocol with OVA sup-
pressed the offspring allergic response, sensitizing 
the offspring at a similar humoral level as previously 
observed by our laboratory in a similar mouse model 
[5, 13]. The protection induced by maternal immuniza-
tion in murine models was previously evidenced by other 
researchers [15]. In contrast, the induction of offspring 
B10 cells that infiltrate more frequently into lung tissue 
of inhibited offspring is unedited evidence. This induc-
tion of B10 cells appears to be specific to OVA because 
maternal immunization with Alum alone or other non-
allergenic protein (MOG) could not induce this cell pop-
ulation in offspring.
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Fig. 2 Role of IL-10 in FcγRIIb expression on B cells and in vitro effect of purified IgG. FcγRIIb expression in response to anti-IgM stimulus was 
assessed in WT and IL-10−/− adult mice (a). Offspring from immunized or non-immunized IL-10−/− mothers were evaluated at 3 days of age or 
immunized with OVA in the neonatal period and evaluated at 20 days of age [20 (Im)]. The total IgE, anti-OVA IgG1 and anti-OVA IgM levels were 
determined by ELISA, and splenic B cell FcγRIIb expression was evaluated by flow cytometry. A representative histogram of FcγRIIb expression in 
each group is shown (b). Identical maternal and neonatal OVA immunization protocols were performed using IL-10−/− females and WT males, and 
splenic B cell FcγRIIb expression in IL-10−/+ offspring was evaluated by flow cytometry analysis (c). Similar maternal and neonatal immunization 
protocols were performed using Dp, and the splenic B10 cell numbers and B cell FcγRIIb expression in offspring were evaluated by flow cytometry 
(d). Offspring splenocytes were cultured for 7 days with 20 µg/mL OVA or 100 µg/mL purified IgG from non-immunized (NO IgG) or immunized 
mothers (IM IgG) with or without FcγRII/III-blocking Ab. The percentage of B10 cells was evaluated by flow cytometry (e). *P ≤ 0.05 compared with 
the offspring of the respective non-immunized mothers. #P ≤ 0.05 compared with the respective result from the sample without FcγR-blocking Ab
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Both human and murine B10 cells have been shown to 
produce large amounts of IL-10 and to exert an inhibi-
tory effect on allergy development. Furthermore, B10 cell 
activity is related to the regulation of IgE production, as 
demonstrated in an atopic dermatitis-like mouse model 
[16].
We previously used a similar preconception allergen 
immunization protocol with BALB/c mice to reveal that 
maternal immunization is associated with an upregu-
lation of FcγRIIb in offspring B cells [7]. However, at 
that time, we were unable to elucidate the mechanism 
through which this phenotype was induced.
Using IL-10−/− mice, we found that IL-10 appears 
to be necessary for the upregulation of FcγRIIb expres-
sion in murine B cells, as observed in WT offspring from 
OVA-immunized mothers. To assess the contribution of 
IL-10 in vivo, IL-10−/− mice were subjected to a mater-
nal and neonatal immunization protocol with OVA, 
which resulted in high IgE production and an opposite 
effect on FcγRIIb expression in offspring B cell compared 
with the WT animals. Furthermore, the downregulation 
of FcγRIIb expression was not reversed in partially-IL-
10-producing offspring derived from IL-10−/− mothers 
mated with WT males (IL-10−/+).
These data suggest the involvement of IL-10 in the reg-
ulation of FcγRIIb receptors on offspring B cells and that 
induced B10 cells can play a pivotal role in offspring as 
the main source of IL-10 to induce the regulatory effect 
of maternal immunization on offspring B cells.
The role of B10 cell induction on allergy inhibition in 
offspring is further reinforced by the results obtained 
from the neonatal Dp immunization of offspring derived 
from Dp-immunized mothers. The opposite effect of Dp 
on FcγRIIb expression in offspring B cells relative to that 
obtained with OVA preconception immunization was 
recently described by our research group [17]. In this 
study, we utilized a similar murine protocol with a lower 
Dp immunization dose and evaluated the frequency of 
B10 cells in offspring.
This evaluation revealed that maternal immuniza-
tion with allergen extracts does not induce a specific 
B10 concomitantly to the reduced levels of FcγRIIb. This 
result suggests that the induction of B10 cells in response 
to allergen is important in FcγRIIb upregulation. The 
absence of B10 cell induction might also explain why 
anti-Dp IgE inhibition is not sustained after the weaning 
period, as we previously observed with the Dp murine 
model [5]. Dp is unable to induce B10 cells potentially 
due to the higher epitope diversity of Dp compared with 
that of the purified allergen OVA, but further experi-
ments using purified allergenic proteins must be under-
taken to support this hypothesis.
Since 2003, our laboratory has suggested that maternal 
IgG plays a role in offspring allergy inhibition that might 
include other mechanisms in addition to direct the avoid-
ance of offspring sensitization due to allergen neutraliza-
tion [4, 5, 7, 18, 19]. More than 15 years ago, Stadler and 
coworkers discussed the role of anti-idiotypic antibodies 
as regulators of IgE production [20]. Our in vitro results 
reveal that B cells of offspring from immunized moth-
ers presented a higher B10 cell percentage in response to 
OVA or maternal IgG. This finding suggests an antigen-
specific response by B10 cells, which engage the B cell 
receptor (BCR) through direct recognition of the aller-
gen, or by allergen-specific IgG, which might idiotypi-
cally interact with BCR.
Consistent with these lines of evidence, the production 
of IL-10 by B10 cells was recently shown to be depend-
ent on the BCR signaling pathway, and its function can 
inhibit murine allergies and autoimmunity [21]. The 
induction and/or maintenance of B10 cells in response 
to specific IgG is unprecedented in the literature and 
appears to be counter-regulated by FcγRIIb expression 
because the blockage of FcγRIIb resulted in higher lev-
els of B10 cells even in offspring from non-immunized 
mothers.
In the present study, we did not evaluate whether off-
spring IgG also plays a role in self B10 cells, but such 
a role is likely because offspring IgG directly reflects 
the maternal immune repertoire [22] via a mechanism 
referred to as maternal imprinting.
Together and in general, these results suggest an aller-
gen-specific regulatory mechanism controlled mainly by 
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Fig. 3 In vitro effect of human purified IgG from atopic and non-
atopic individuals. PBMCs from atopic or non-atopic individuals were 
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of 100 µg/mL purified IgG from non-atopic (nAtIgG) or atopic (AtIgG) 
individuals, and the frequency of intracellular IL-10 in B cells was 
evaluated by flow cytometry. *P ≤ 0.05 compared with the mock 
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specific IgGs that are responsible for the maintenance 
and/or induction of allergen-specific B10 cells. The 
recently proposed “MatIgG primary modulation theory” 
describes this mechanism [23].
The production of IL-10 by B10 cells in response to 
allergens plays a pivotal role in allergy inhibition. Sev-
eral years ago, Verhasselt and colleagues suggested that 
the maternal allergen-IgG immune complex transferred 
to offspring by breast feeding can induce tolerance in the 
offspring without interaction with FcγRIIb receptors [15]. 
Based on our results, it is possible that the induction of 
Breg cells could also be involved in the cited work, but 
the previous study only evaluated Treg cell induction.
In our model, we did not evaluate the impact of breast 
feeding only. Previous results obtained by our research 
group in a similar murine model revealed that an off-
spring derived from a non-immune mother and nursed 
by an OVA-immunized mother presents an allergen-
specific anaphylactic IgE response that is suppressed at 
a level similar to those observed in offspring that were 
delivered and nursed by a OVA-immunized mother [6]. 
In the present work, we found that B10 cell induction 
can be accessed on 3-day-old offspring from immune 
mothers, which suggests that the proposed induction 
of B10 cells is mediated mainly by the transplacental 
transference of maternal IgG, but we cannot discard the 
possibility that milk IgG could also participate in the 
maintenance and/or induction of this mechanism.
Because this hypothesis has not been discussed in a 
human context, we evaluated atopic and non-atopic indi-
viduals in search of corroborating evidence and found 
that only peripheral B cells from non-atopic individuals 
can produce IL-10 in response to autologous IgG. This 
finding is unprecedented in the literature and suggests 
that B cells from non-atopic individuals have the poten-
tial to produce IL-10 in response to the IgG repertoire, 
as observed in our murine model. Based on our experi-
mental evidence, we believe that this response can aid 
the maintenance of a non-atopic immune status. The 
protective effect of maternal passively transferred IgG 
induced by allergen immunotherapy in humans has been 
described in the literature [24, 25], but a possible mech-
anism for B10 cell induction in humans has not been 
described.
Conclusions
In conclusion, our results reveal that maternal immuni-
zation with allergens can induce B10 cells that respond to 
allergen or allergen-specific IgG. This response is unprec-
edented and occurs in mice and humans, revealing a pos-
sible mechanism for allergy inhibition that will yield new 
targets for the future development of allergy inhibition 
protocols.
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